期刊
VIRUS RESEARCH
卷 102, 期 1, 页码 37-42出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.virusres.2004.01.013
关键词
influenza virus; siRNA; prophylaxis; therapy; delivery
类别
资金
- NCI NIH HHS [CA60686] Funding Source: Medline
- NIAID NIH HHS [AI44478, AI44477, AI50631, AI40146] Funding Source: Medline
Influenza virus causes one of the most prevalent infections in humans. In a typical year, 10-20% of the population in the United States are infected by influenza virus. resulting in up to 40,000 deaths. Current vaccines can prevent illness in approximately 70-80% of healthy individuals under age 65, but the protection rate is much lower in those most susceptible to infection, namely infants, the elderly, and immunocompromised individuals. Although four antiviral drugs have been approved in the United States for treatment and/or prophylaxis of influenza. their use is limited because of concerns about side effects, compliance, and the possible emergence of resistant virus. We found that short interfering RNAs (siRNAs) specific for conserved regions of the influenza virus genome are potent inhibitors of influenza virus replication in both cell lines and embryonated chicken eggs. In this review. we discuss the potential value of siRNAs for preventing and treating influenza virus infections in humans and the challenges that have to be overcome to realize their potential. (C) 2004 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据